Genewiz has launched Gene Synthesis 2.0, a platform that upgrades its gene synthesis service with enhanced codon optimization. The new system blends heuristic methods with machine learning models trained on a high-expression dataset.
The technology aims to improve expression reliability across a broad range of organisms, potentially accelerating research in synthetic biology and therapeutic protein production. By leveraging AI, Gene Synthesis 2.0 addresses a longstanding bottleneck in gene design.
This launch marks a step forward in commercial gene synthesis, where accuracy and expression predictability are critical. The platform could reduce trial-and-error in cloning and protein engineering workflows.
For Genewiz, a provider of genomic services, the upgrade strengthens its position in the competitive synthetic biology market. It signals a trend toward AI-driven tools in gene design, likely pressuring rivals to innovate.
While the announcement lacks specific performance metrics, the integration of machine learning represents a notable shift. One caveat is that real-world validation across diverse cell types remains to be demonstrated independently.